Cara Therapeutics

ACTIVE

400 Atlantic St Ste 500, 康涅狄格州费尔菲尔德县, 康涅狄格州, United Stateswww.caratherapeutics.comPublic55 employeesEstablished: 2004-07-02$19.7M

Also known as:

cara therapeutics inc

cara-us

cara

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Clinical Trials

11 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2004

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

38.9%

Phase 2

36.1%

Phase 3

22.2%

Trial Status Distribution

Active, not recruiting

30.6%

Approved For Marketing

2.8%

Completed

52.8%

Terminated

13.9%

Clinical Trials

Trials sponsored by this organization (36)

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

Phase 2

Terminated

interventional

Aug 2023214 participants

This is a clinical trial (study), to be conducted in several clinical sites worldwide, of an oral study drug which will be investigated in adult patients with moderate to severe pruritus (itching) associated with Notalgia Paresthetica to assess if it's effective and safe.

Phase 1

Active, not recruiting

interventional

Jun 2023577 participants

A Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Severe Pruritus with an up to 52-Week Long-term Extensio

Phase 1

Active, not recruiting

Dec 2022400 participants

A Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Severe Pruritus and not on Dialysis with an up to 52-Week Long-term Extensio

Phase 1

Active, not recruiting

Nov 2022400 participants

A Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Severe Pruritus with an up to 52-Week Long-term Extensio

Phase 1

Active, not recruiting

Nov 2022400 participants

CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Phase 3

Terminated

interventional

Aug 2022105 participants

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Phase 3

Terminated

interventional

Aug 2022287 participants

A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Phase 3

Terminated

interventional

May 2022286 participants

Page 1 of 5

Approvals

No approval data available

News

Tvardi Therapeutics Completes Merger with Cara, Advances STAT3 Inhibitor Programs for Fibrosis-Driven Diseases

- Tvardi Therapeutics has completed its merger with Cara Therapeutics, creating a Nasdaq-listed company focused on developing STAT3 inhibitors for fibrosis-driven diseases, with shares trading under the ticker "TVRD." - The combined company has secured approximately $52 million in funding through the merger and a private placement, providing runway into the second half of 2026 through two anticipated Phase 2 data readouts. - Tvardi's lead clinical programs include Phase 2 trials of its oral STAT3 inhibitor TTI-101 in idiopathic pulmonary fibrosis (data expected 2H 2025) and hepatocellular carcinoma (data expected 1H 2026).

Apr 15, 2025

Back to Organizations